Le Lézard
Classified in: Health, Science and technology
Subject: SLS

SOM Biotech Achieves Relevant Advances in its Pipeline Leveraging on its Proprietary AI-based Drug Discovery Technology SOM[AI]- PRO


BARCELONA, Spain, Jan. 13, 2020 /PRNewswire/ -- SOM Biotech, a clinical-stage drug discovery and development company focused on orphan diseases, closes a remarkable year, achieving relevant advances in its drug development pipeline leveraging on its proprietary AI-based drug discovery technology SOMAI-PRO.

SOM_Biotech_Logo

According to Raul Insa ? CEO of SOM Biotech ?, "2019 has been a great year, in which we have achieved major milestones in our pipeline development, that prove that our drug discovery strategy creates value from the very beginning of the entire process of identifying new candidate therapeutics for treating human diseases. We are using our proprietary technology - SOMAI-PRO - which ensures the highest predictivity in the identification of active molecules. SOMAI-PRO has allowed us to successfully finish the clinical phase 2a of two drugs with very positive results, which will contribute to treat two relevant neurodegenerative diseases more effectively, meeting high safety and tolerance standards."

Maria Zimina ? Business Development Manager ? underlines: "We successfully apply SOMAI PRO technology to identify drugs for the treatment of a specific disease, and to discover new mechanisms of action and new applications for a drug. The main strength of our AI technology is that it identifies the mechanisms of action (biological activity) of molecules and determines its non-structural analogs with similar biological activity. It allows us to identify effective drugs as well as new applications for drugs with a very high likelihood of success and reliable patent protection. This is a key differentiating factor in relation to most of other AI-based approaches, which use methods based on data mining, structural similarity, or the target structure. 

Although we have focused our activities in re-innovating drugs to treat orphan diseases, we want to extend the scope of our drug discovery efforts. As a validated technology, SOMAI-PRO is suited to be applied for any therapeutic area and for new chemical entities. Specially, the latter is a clear competitive advantage which will enable us to accelerate and optimize drug discovery.

We aim at developing value creating partnerships with strategic partners, to leverage on the large intrinsic potential of SOMAI-PRO to discover new treatments to tackle some of the most acute diseases."

About SOM Biotech

SOM Biotech (www.sombiotech.com) ? established in 2009 - is a biopharmaceutical company based in Barcelona, Spain. SOM has an extensive portfolio of products that includes drugs for orphan diseases including TTR Amyloidosis, Huntington's disease, Adrenoleukodystrophy, Phenilketonuria, Niemann Pick, and Glioblastoma. The company engages in accelerated discovery of therapies through a proprietary artificial intelligence-based computational technology and develops strategic partnerships with major research centers and pharmaceutical companies

Media contact:
Katja Görnemann
[email protected] 
Tel: +34-696135428

SOURCE SOM Biotech


These press releases may also interest you

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...

at 03:13
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is...

at 03:05
Surge has just closed its second round of funding, raising ?7.5 million. The round was led by Eurazeo with the participation of Kima, Teampact, and MH Innov', as well as the support of historical funds Boutique Venture, HCVC, and 50 Partners Santé....

at 03:00
CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who...



News published on and distributed by: